Table 2.
IgG index following SARS-CoV-2 vaccination or COVID-19.
| IgG AU/mL Mean ± SE [range] (% IgG positive) | Post COVID-19 no vaccine | Time-point 1: ≤3m Post 2nd vaccine | Time-point 2: ~6m Post 2nd vaccine | Time-point 3: ≤3m Post 3rd vaccine |
|---|---|---|---|---|
| MS patients | ||||
| Untreated | N=2 | N=28 | N=17 | N=14 |
| 661 ± 480 | 7778 ± 1502 | 1269 ± 681 | 18640 ± 4167 | |
| [180 – 1141] | [770 – 32497] | [120 – 12046] | [454 – 40000] | |
| (100%) | (100%) | (100%) | (100%) | |
| Alemtuzumab | N=2 | N=3 | N=1 | |
| 73 ± 0 | 8414 ± 3888 | 1366 | ||
| [73−73] | [761 – 13329] | (100%) | ||
| (100%) | (100%) | |||
| Anti CD-20 mAb (Ocrelizumab) | N=13 | N=89 | N=38 | N=43 |
| 709 ± 586 | 290 ± 113 | 137 ± 37 | 2072 ± 938 | |
| [0 – 7722] | [0 − 7722] | [0 – 992] | [0 – 36108] | |
| (54%) | (38%) | (42%) | (44%) | |
| Anti CD-20 mAb (Ofatumumab) | N=4 | N=2 | ||
| 2120 ± 1344 | 5210 ± 5021 | |||
| [120 – 5826] | [189−10230] | |||
| (100%) | (100%) | |||
| Cladribine | N=3 | N=23 | N=11 | N=9 |
| 13661 ± 13172 | 5923 ± 1096 | 806 ± 181 | 9826 ± 2691 | |
| [44 – 40000] | [162 – 22148] | [42 – 1991] | [643 – 23144] | |
| (67%) | (100%) | (91%) | (100%) | |
| Dimethyl Fumarate | N=2 | N=52 | N=28 | N=32 |
| 181 ± 75 | 8401 ± 1217 | 708 ± 139 | 13813 ± 2226 | |
| [106 – 256] | [610 – 32938] | [6 – 3813] | [420 – 40000] | |
| (100%) | (100%) | (96%) | (100%) | |
| Glatiramer Acetate | N=22 | N=9 | N=8 | |
| 6984 ± 1577 | 1283 ± 633 | 10748 ± 2567 | ||
| [153 – 33131] | [152 – 6146] | [2902 – 21115] | ||
| (100%) | (100%) | (100%) | ||
| Interferon β (Avonex, Plegridy, Betaferon, Rebif) | N=1 | N=19 | N=15 | N=13 |
| 22699 | 7832 ± 2182 | 1649 ± 971 | 16509 ± 3639 | |
| (100%) | [248 – 40000] | [35 – 14783] | [1649 – 40000] | |
| (100%) | (93%) | (100%) | ||
| Natalizumab | N=3 | N=19 | N=12 | N=14 |
| 288 ± 164 | 9698 ± 2458 | 1372 ± 573 | 7149 ± 2592 | |
| [90 – 614] | [161 – 40000] | [259 – 7258] | [792 – 33990] | |
| (100%) | (100%) | (100%) | (100%) | |
| S1PR modulator (Fingolimod) | N=4 | N=37 | N=13 | N=24 |
| 298 ± 164 | 1494 ± 670 | 200 ± 143 | 325 ± 191 | |
| [29 – 777] | [0 – 19543] | [0 – 1856] | [0 – 4586] | |
| (75%) | (54%) | (31%) | (46%) | |
| S1PR modulator (Siponimod) | N=1 | N=3 | N=1 | |
| 25 | 1278 ± 1095 | 52 | ||
| (0%) | [69−3464] | (100%) | ||
| (100%) | ||||
| Teriflunomide | N=15 | N=7 | N=10 | |
| 6054 ± 1356 | 2063 ± 1240 | 13886 ± 4039 | ||
| [439 – 16216] | [244 – 9366] | [568 – 40000] | ||
| (100%) | (100%) | (100%) | ||
| Healthy | N=53 | N=16 | N=21 | |
| 3537 ± 725 | 855 ± 371 | 10765 ± 2096 | ||
| [42 – 27876] | [108 – 5790] | [787 – 33761] | ||
| (98%) | (100%) | (100%) | ||
AU, arbitrary units; IgG, immunoglobulin G; m, months; mAb, monoclonal antibody; SE, standard error; S1P, Sphingosine 1-phosphate receptor.